Announced Tue, 11 Aug · 18:38 IST
No deviation in fund use for Q1FY27 across three tranches
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.7%1-day move
₹39.25
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-5.7-3.3-4.4-3.2-3.2-3.2-3.1-5.8——
Up moveDown movePending
AI summary
Sandu Pharmaceuticals filed Q1FY27 (quarter ended 30 June 2026) statement of deviation and use of funds from preferential issues. Three tranches: Rs 2.64 cr (Mar-2021), Rs 1.38 cr (Feb-2022), Rs 1.32 cr (Jul-2022). All three report NO deviation; proceeds are being used for plant and machinery, marketing infra, working capital, technology, and general purposes as originally planned. Audit Committee approved, auditors had no comments. Unutilized funds remain in escrow FD at Bank of Baroda.
Likely market impact
Routine compliance filing. No fund misuse flagged; management is deploying raised capital as planned. Neutral for shareholders.